Rui Liao1, Xing-Diao Zhang2, Gui-Zhong Li3, Ke-Le Qin1, Xiong Yan1. 1. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 2. Department of General Surgery, Dazhou Central Hospital, Dazhou, China. 3. Department of General Surgery, Beibei Traditional Chinese Medicine Hospital, Chongqing, China.
Abstract
BACKGROUND: There is still no general consensus on the optimal chemotherapeutic agent selection for transcatheter arterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC). The present study aimed to compare the efficacy and safety of TACE with raltitrexed plus liposomal doxorubicin (R + PGLD) vs. tegafur plus pirarubicin (T + P) in patients with unresectable HCC. METHODS: A total of 148 patients with unresectable HCC treated with TACE between January 2012 and December 2016 were retrospectively analyzed. Of them, 74 patients were in the R + PGLD group and 74 patients were in the T + P group (1:1). The treatment response of the tumor, overall survival (OS) time, and adverse effects were compared between the two groups. RESULTS: There were no significant differences in patient characteristics or embolization effect (lipiodol deposition) between the two groups (P>0.05). R + PGLD treatment had a better clinical efficacy than T + P treatment (OR: 64.9% vs. 45.9%, P=0.031; DC: 89.2% vs. 74.3%, P=0.032). Portal vein invasion, hepatic vein invasion, tumor size and BCLC stage were associated with OR or DC after TACE using R + PGLD treatment. Survival analysis revealed that patients who received TACE with R + PGLD had a better prognosis than those treated with T + P. Moreover, some complications in the R + PGLD group, including vomiting, myelosuppression and cardiotoxicity, were significantly lower than those in the T + P group (P<0.05). CONCLUSIONS: TACE with raltitrexed and liposomal doxorubicin could reduce the incidence of adverse reactions and significantly improve the OS of patients with unresectable HCC. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: There is still no general consensus on the optimal chemotherapeutic agent selection for transcatheter arterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC). The present study aimed to compare the efficacy and safety of TACE with raltitrexed plus liposomal doxorubicin (R + PGLD) vs. tegafur plus pirarubicin (T + P) in patients with unresectable HCC. METHODS: A total of 148 patients with unresectable HCC treated with TACE between January 2012 and December 2016 were retrospectively analyzed. Of them, 74 patients were in the R + PGLD group and 74 patients were in the T + P group (1:1). The treatment response of the tumor, overall survival (OS) time, and adverse effects were compared between the two groups. RESULTS: There were no significant differences in patient characteristics or embolization effect (lipiodol deposition) between the two groups (P>0.05). R + PGLD treatment had a better clinical efficacy than T + P treatment (OR: 64.9% vs. 45.9%, P=0.031; DC: 89.2% vs. 74.3%, P=0.032). Portal vein invasion, hepatic vein invasion, tumor size and BCLC stage were associated with OR or DC after TACE using R + PGLD treatment. Survival analysis revealed that patients who received TACE with R + PGLD had a better prognosis than those treated with T + P. Moreover, some complications in the R + PGLD group, including vomiting, myelosuppression and cardiotoxicity, were significantly lower than those in the T + P group (P<0.05). CONCLUSIONS: TACE with raltitrexed and liposomal doxorubicin could reduce the incidence of adverse reactions and significantly improve the OS of patients with unresectable HCC. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Jens Ricke; Heinz Josef Klümpen; Holger Amthauer; Irene Bargellini; Peter Bartenstein; Enrico N de Toni; Antonio Gasbarrini; Maciej Pech; Markus Peck-Radosavljevic; Peter Popovič; Olivier Rosmorduc; Eckart Schott; Max Seidensticker; Chris Verslype; Bruno Sangro; Peter Malfertheiner Journal: J Hepatol Date: 2019-08-14 Impact factor: 25.083
Authors: Jean-Luc Raoul; Alejandro Forner; Luigi Bolondi; Tan To Cheung; Roman Kloeckner; Thierry de Baere Journal: Cancer Treat Rev Date: 2018-11-12 Impact factor: 12.111
Authors: Peter R Galle; Francesco Tovoli; Friedrich Foerster; Marcus A Wörns; Alessandro Cucchetti; Luigi Bolondi Journal: J Hepatol Date: 2017-03-18 Impact factor: 25.083
Authors: Won Young Tak; Shi-Ming Lin; Yijun Wang; Jiasheng Zheng; Aldo Vecchione; Soo Young Park; Min Hua Chen; Stephen Wong; Ruocai Xu; Cheng-Yuan Peng; Yi-You Chiou; Guan-Tarn Huang; Jianqiang Cai; Basri Johan Jeet Abdullah; June Sung Lee; Jae Young Lee; Jong-Young Choi; Julieta Gopez-Cervantes; Morris Sherman; Richard S Finn; Masao Omata; Michael O'Neal; Lukas Makris; Nicholas Borys; Ronnie Poon; Riccardo Lencioni Journal: Clin Cancer Res Date: 2017-10-10 Impact factor: 12.531